Navigation Links
Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
Date:9/26/2011

relief, so a new therapy like EXPAREL, which blocks the pain at its source for up to three days and potentially reduces the need for opioids, could be a game changer."

Also at ASPS, new data from a two-year observational study of EXPAREL following breast augmentation were presented during an oral session on Saturday, September 24, 2011. The study, a long-term follow-up of 94 subjects enrolled in prior Phase 2 and Phase 3 studies who underwent breast augmentation at multiple sites in the U.S. and received either bupivacaine or EXPAREL, evaluated patients from 13 to 24 months following surgery; new key finding include:

  • EXPAREL did not have any impact on normal healing in the presence of silicone breast implant material.
  • There was no meaningful difference in impact on breast appearance or implant material in the bupivacaine versus EXPAREL groups.
  • Neither EXPAREL nor bupivacaine were associated with any serious adverse events, deaths or withdrawals from the study.

"EXPAREL represents a much needed advance in perioperative, site-specific pain relief therapies, and this study demonstrates the long-term safety profile of EXPAREL following breast augmentation," said Harold Minkowitz, M.D., the study's lead author and a staff anesthesiologist at Memorial Hermann Memorial City Medical Center in Houston, Texas. "After evaluating patients for up to two years after the procedure, we concluded that EXPAREL did not interfere with the patient's healing process or the integrity of the implant material, and was not associated with any late-stage adverse events."

According to the ASPS, breast augmentation has been the most performed cosmetic surgical procedure since 2006. In 2010, approximately 296,000 breast augmentations were performed, 60 percent of which used silicone implants.(1) In the last decade, the number of breast augmentations performed has increased by 39 percent.(1)

"We are
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015 Research ... addition of the  "North America Mammography Market ... 2019)"  report to their offering. ... is a detailed type of imaging that ... breasts. A mammography exam, called a mammogram, ...
(Date:5/27/2015)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life sciences ... of innovative products and services, today announced that its ... operations in Grand Rapids, Michigan ... , North Carolina.  Sequenom Laboratories, cystic fibrosis carrier screen ... North Carolina laboratory location.  "The ...
(Date:5/27/2015)... YORK , May 27, 2015 PharmaPoint: Type ... 2023 Summary Type 1 diabetes (T1D) is an ... islet, which means that the body can no longer produce ... evolving continuously, as at present, no other treatment can be ... A variety of insulin analogs with different times of action ...
Breaking Medicine Technology:North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 2Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4
... 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky ... leading fully integrated pharmaceutical company producing over-the-counter drugs in the ... the fourth quarter and fiscal year ended December 31, 2010. ... 2010 Highlights Total revenues decreased by ...
... 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... Trademark Office (USPTO) has issued U.S. Patent 7,906,489 which ... treatment with fidaxomicin.  The patent, which is eligible for ... Book, also received a term adjustment of an additional ...
Cached Medicine Technology:China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results 2China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results 3China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results 4China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results 5China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results 6China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results 7China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results 8China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results 9China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results 10China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results 11China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results 12China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results 13China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results 14Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection 2
(Date:5/27/2015)... 27, 2015 “We are honored to ... executive vice president and vice president of clinical affairs ... possible allows us to provide comprehensive care to more ... , SSCHC provides clinical care and behavioral health services ... in 2014, many of whom took advantage of the ...
(Date:5/27/2015)... 2015 Continuing its commitment to finding ... in the community, SmartPractice® donated $25,000 to ... Lincoln). SmartPractice Vice President of Human Resources Meg Mosher ... $25,000 check to Paulla Miller, Sherry Gage, Dr. Linda ... Research Center on April 30. The center is located ...
(Date:5/27/2015)... 2015 In today's healthcare landscape, where ... can be challenging for doctors and hospitals to keep ... , Austin-based HealthTronics, Inc. is offering ... medical therapies for clinically sophisticated applications. The company has ... of Laser Ventures, Inc ., a mobile laser ...
(Date:5/27/2015)... The new http://www.carsonenergy.com includes extensive ... consider oil and gas investing, the substantial tax benefits ... industry news, IRA investing, definitions and acronyms, info-graphics and ... and experience is now in one central location, for ... to access 24 hours a day, 7 days a ...
(Date:5/27/2015)... 27, 2015 In support of a ... issue of the Journal of American Geriatrics Society about ... obesity, Bedford Commons OB-GYN P.A . is reiterating ... sweetener-flavored beverages. , To examine the relationship between ... San Antonio Longitudinal Study of Aging (SALSA) tracked the ...
Breaking Medicine News(10 mins):Health News:Sixteenth Street Community Health Centers To Expand Primary Care and Behavioral Health Services Through $1 Million Grant From Aurora's Better Together Fund 2Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2
... Solos Endoscopy, Inc. (OTCPK:,SNDY) is pleased to announce ... for the period ending June 30, 2008. Revenues,generated through ... $151,347.53 for the comparable period in 2007. The Company,saw ... $13,242 compared with just,over $8,000 at the end of ...
... there are no safe substitutes for authentic,FDA approved ... unbranded,unapproved and counterfeit cosmetic injectables are a threat ... Coalition for Injectable Safety. "The,growing acceptance of cosmetic ... comes with consumer cautions," says Coalition,leader, plastic surgeon ...
... October 7, 2008 Extreme heat events (EHE), or ... human mortality in the United States, responsible for more ... combined. These events, and other climate-related changes in the ... in the November issue of the American Journal ...
... Hong Kong Celebrates a Wealth of Innovative Products, ... world leader in,research and development, announces today that it ... October 2008 at Gordon Wu Hall, B P,International House ... Founded in 1902 in Minnesota, United States, 3M has ...
... 8 A recent study comparing eight,leading ... prescription packages that could impact patient safety ... are contained in them., Pharmacy Healthcare ... Pittsburgh, PA, conducted a study to analyze ...
... Orthopedics, Inc. today,announced the first human use of ... The landmark case was performed by Dr. Karin,Buttner-Janz, ... the Vivantes,Clinic in Berlin, Germany, and involved a ... developed symptomatic facet joint,degeneration. "Generally in this situation ...
Cached Medicine News:Health News:Solos Endoscopy, Inc. Posts First Six Months Financials of 2008 on Pinksheets.com 2Health News:Illegal Botox Scammers a Public Threat 2Health News:Illegal Botox Scammers a Public Threat 3Health News:Illegal Botox Scammers a Public Threat 4Health News:Illegal Botox Scammers a Public Threat 5Health News:Climate change will affect public health -- a call to action 2Health News:Climate change will affect public health -- a call to action 3Health News:3M Innovation Day 2Health News:3M Innovation Day 3Health News:Test Results from Pharmacy Healthcare Solutions Show not all Prescription Packaging is Created Equal 2Health News:Archus Orthopedics Performs First Facet Replacement Procedure With an Artificial Disc 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: